Nootropic
A substance claimed to improve cognitive function including memory, attention, and motivation. Several research peptides (selank, semax) are discussed as nootropics, but most lack rigorous clinical trial evidence. The distinction between evidence-based cognitive therapeutics and unvalidated claims is important.
Technical Context
The original Giurgea criteria for nootropics: enhance learning and memory, protect the brain from physical/chemical injury, enhance tonic cortical/subcortical control mechanisms, lack usual pharmacological effects of psychotropic drugs (sedation, motor stimulation), and possess very few side effects with extremely low toxicity. Few substances meet all criteria. In the peptide space: selank (synthetic derivative of tuftsin/immunoglobulin fragment) is approved in Russia as an anxiolytic/nootropic; semax (synthetic ACTH analogue fragment) is approved in Russia for cognitive enhancement and stroke recovery — neither has FDA/EMA approval due to insufficient evidence by Western regulatory standards. The evidence gap between Russian-approved peptide nootropics (typically based on smaller, non-Western trials) and FDA/EMA standards (requiring large, multicentre, placebo-controlled Phase III trials) is significant and important for evidence-informed evaluation.